Entry into or termination of material definitive agreements (Items 1.01/1.02).
SoFi Technologies, Inc. entered into Indenture with U.S. Bank Trust Company, National Association (effective 2024-03-08).
“The notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of March 8, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee”
Academy Sports & Outdoors, Inc. amended ABL Amendment with JPMorgan Chase Bank, N.A. (effective 2024-03-08).
“On March 8, 2024 Academy, Ltd. (“Academy”), a wholly-owned subsidiary of Academy Sports and Outdoors, Inc. (the “Company”), as borrower, New Academy Holding Company, LLC, Associated Investors, L.L.C. and Academy Managing Co., L.L.C., each a direct or indirect, wholly-owned subsidiary of the Company, as guarantors, entered into an amendment (the “ABL Amendment”) to the First Amended and Restated ABL Credit Agreement, dated as of July 2, 2015, with JPMorgan Chase Bank, N.A. as the administrative agent and collateral agent, letter of credit issuer and swingline lender, and the several lenders party thereto”
MP Materials Corp. / DE entered into Capped Call Transactions with certain financial institutions (collectively, the 'Counterparties') valued at approximately $65.3 million (effective 2024-03-04).
“On March 6, 2024, in connection with the Initial Purchasers’ exercise of their option to purchase the Additional Notes, the Company entered into privately negotiated additional capped call transactions (the “Additional Capped Call Transactions,” and together with the Base Capped Call Transactions, the “Capped Call Transactions”) with the Counterparties.”
MP Materials Corp. / DE entered into Indenture with U.S. Bank Trust Company, National Association (effective 2024-03-07).
“The Company issued the Notes under an indenture, dated as of March 7, 2024 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”
New Fortress Energy Inc. entered into 8.750% Senior Secured Notes due 2029 Indenture with U.S. Bank Trust Company, National Association valued at $750,000,000 aggregate principal amount of 8.750% senior secured notes due 2029 (effective 2024-03-08).
“On March 8, 2024 (the “Issue Date”), New Fortress Energy Inc. (the “Company”) closed its previously announced private offering of $750,000,000 aggregate principal amount of 8.750% senior secured notes due 2029 (the “Notes”). The Notes were issued pursuant to an indenture, dated as of March 8, 2024 (the “Indenture”), by and among the Company, the subsidiary guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and as notes collateral agent.”
Sharps Technology Inc. entered into Logistics Services Agreement with Owens & Minor Distribution, Inc. (effective 2024-03-08).
“On March 8, 2024, the Company entered into a logistics service agreement with Owens & Minor Distribution, Inc., (hereinafter “O&M”) for the Company’s use of O&M’s logistics services.”
Sharps Technology Inc. entered into Cooperative Sales and Distribution Agreement with Roncadelle Operations s.r.l. (effective 2024-03-04).
“On March 4, 2024 (the “Effective Date”), Sharps Technology, Inc. (and its wholly-owned subsidiary Sharps Technology Acquisition Corp., collectively, (the “Company”) entered into a Cooperative Sales and Distribution agreement (the “Agreement) with Roncadelle Operations s.r.l (hereinafter, “ROP”).”
bioAffinity Technologies, Inc. entered into Securities Purchase Agreement with four institutional investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2024-03-06).
“On March 6, 2024, bioAffinity Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with four institutional investors (the "Purchasers"), pursuant to which the Company will issue to the Purchasers, (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock (the "Shares"), par value $0.007 per share ("Common Stock") and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the "Common Warrants") with an exercise price of $1.64.”
VICI PROPERTIES INC. entered into Underwriting Agreement with Wells Fargo Securities, LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and Goldman Sachs & Co. LLC, as representatives of the several underwriters valued at $550 million aggregate principal amount of 5.750% Senior Notes due 2034 and $500 million aggregate p (effective 2024-03-07).
“entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and Goldman Sachs & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), pursuant to which VICI LP agreed to issue and sell $550 million aggregate principal amount of 5.750% Senior Notes due 2034”
Quoin Pharmaceuticals, Ltd. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of 7.0% of the aggregate gross proceeds (effective 2024-03-04).
“Pursuant to that certain placement agency agreement, dated March 4, 2024, by and between the Company and the Placement Agent (the "Placement Agency Agreement"), the Placement Agent was paid a cash fee of 7.0% of the aggregate gross proceeds to the Company from the sale of the ADSs, Pre Funded-Funded Warrants and Warrants in the Offering and the Company reimbursed the Placement Agent for (i) non-accountable expenses in an amount of 1.0% of the aggregate gross proceeds raised in the Offering and (ii) accountable expenses of the Placement Agent of $125,000 related to the legal fees.”
LivaNova PLC entered into Indenture with Citibank, N.A., as trustee valued at $345 million aggregate principal amount (effective 2024-03-08).
“On March 8, 2024, LivaNova PLC (“LivaNova”) issued $345 million aggregate principal amount of its 2.50% convertible senior notes due 2029 (the “Notes”), including $45 million aggregate principal amount issued pursuant to the exercise in full of the initial purchasers’ option to purchase additional Notes. The Notes were issued pursuant to an indenture, dated as of March 8 , 2024 (the “Indenture”), between LivaNova and Citibank, N.A., as trustee.”
Sabre Corp entered into First Supplemental Indenture with Computershare Trust Company, N.A. valued at approximately $50.1 million (effective 2024-03-07).
“Sabre GLBL issued approximately $50.1 million in additional aggregate principal amount of its 8.625% Senior Secured Notes due 2027”
Avinger Inc entered into Securities Purchase Agreement with Zylox-Tonbridge Medical Limited valued at $15 million (effective 2024-03-04).
“the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the “Purchaser”), entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company’s common stock”
Avinger Inc entered into Strategic Cooperation and Framework Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
“on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the “Collaboration Agreement””
Avinger Inc entered into License and Distribution Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
“On March 4, 2024, Avinger, Inc. (“Avinger” or the “Company”) entered into a License and Distribution Agreement (the “License Agreement”) with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) effective as of the Initial Closing (defined below)”
Kosmos Energy Ltd. entered into Indenture with Wilmington Trust, National Association valued at $400 million aggregate principal amount (effective 2024-03-08).
“The Company issued such Notes under the indenture dated March 8, 2024 (the “Indenture”) among the Company, the guarantors named therein (the “Guarantors”) and Wilmington Trust, National Association, as trustee.”
OptiNose, Inc. amended Second Amendment with BioPharma Credit PLC (effective 2024-03-08).
“On March 8, 2024, OptiNose, Inc. (the “Company”) entered in a Second Amendment (the “Second Amendment”) to its Amended and Restated Note Purchase Agreement dated November 21, 2022, as amended on March 5, 2024, among the Company, OptiNose US, Inc., the purchaser parties defined therein and BioPharma Credit PLC (as amended, the “A&R Note Purchase Agreement”).”
Sonoma Pharmaceuticals, Inc. amended Amendment No. 1 with Maxim Group LLC valued at up to $785,679 (effective 2024-03-08).
“On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.”
Greystone Housing Impact Investors LP entered into Amended and Restated Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC and BTIG, LLC valued at aggregate offering price of up to $50,000,000 (effective 2024-03-08).
“On March 8, 2024, Greystone Housing Impact Investors LP, a Delaware limited partnership (the “Partnership”), entered into an Amended and Restated Capital on Demand TM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC and BTIG, LLC, as agents (each, an “Agent,” and collectively the “Agents”), pursuant to which the Partnership may offer and sell, from time to time through or to the Agents, beneficial unit certificates representing assigned limited partnership interests (“BUCs”) in the Partnership, having an aggregate offering price of up to $50,000,000 (the “Offering”).”
OLENOX INDUSTRIES INC. entered into Inducement Agreement with a certain holder of warrants to purchase shares of the Company’s common stock valued at approximately $494,213 (effective 2024-03-08).
“On March 8, 2024, Safe & Green Holdings Corp. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with a certain holder (the “Holder”) of warrants to purchase shares of the Company’s common stock”
TYSON FOODS, INC. entered into Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $600,000,000 aggregate principal amount of its 5.400% Senior Notes due 2029 and $900,000,000 aggrega (effective 2024-03-08).
“On March 8, 2024, Tyson Foods, Inc. (the “Company”) completed its previously announced public offerings and sale of $600,000,000 aggregate principal amount of its 5.400% Senior Notes due 2029 (the “2029 Notes”) and $900,000,000 aggregate principal amount of its 5.700% Senior Notes due 2034 (the “2034 Notes” and, together with the 2029 Notes, the “Notes”).”
Resonate Blends, Inc. amended Share Exchange Agreement with Emergent Health Corp. valued at Amendment revised Sections 1.03(d)(v) and 5.05 of the Exchange Agreement to require a minimum invest (effective 2024-03-04).
“On March 4, 2024, Resonate Blends, Inc. (“ we ” or the “ Company ”) entered into an amendment (the “ Amendment ”) to the Share Exchange Agreement (the “ Exchange Agreement ”) with Emergent Health Corp. (“ EMGE ”) and the holders of Series Class A Preferred Stock, the Series C Convertible Non-Voting Preferred Stock and the Class F Preferred Stock of EMGE. The Amendment revised Sections 1.03(d)(v) and 5.05 of the Exchange Agreement to require a minimum investment of $250,000 instead of $500,000 prior to Closing.”
ROYAL CARIBBEAN CRUISES LTD entered into Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $1.25 billion (effective 2024-03-07).
“On March 7, 2024, Royal Caribbean Cruises Ltd. (the “Company”) completed its previously announced offering of $1.25 billion aggregate principal amount of 6.250% Senior Notes due 2032 (the “Notes”).”
MICROCHIP TECHNOLOGY INC entered into First Supplemental Indenture with Computershare Trust Company, National Association valued at $1,000,000,000 aggregate principal amount (effective 2024-03-07).
“On March 7, 2024, Microchip Technology Incorporated, a Delaware corporation (the “Company”), issued $1,000,000,000 aggregate principal amount of its 5.050% Senior Notes due 2029 (the “Notes”) in a public offering.”
Fresh Tracks Therapeutics, Inc. terminated Termination Agreement with Carna Biosciences, Inc. (effective 2024-03-05).
“On March 5, 2024, Fresh Tracks Therapeutics, Inc. (the “Company”) and Carna Biosciences, Inc. (“Carna”) entered into a Termination of License Agreement (the “Termination Agreement”), pursuant to which the parties agreed to terminate, effective as of March 1, 2024, that certain Exclusive License Agreement, dated as of February 2, 2022, by and between Carna and the Company (the “Carna License Agreement”), subject to the survival of certain provisions regarding indemnification, confidentiality, dispute resolution, record retention, audit rights, taxes and ownership of inventions.”
NAPCO SECURITY TECHNOLOGIES, INC entered into Underwriting Agreement with Needham & Company, LLC and Cowen and Company, LLC (effective 2024-03-05).
“On March 5, 2024, NAPCO Security Technologies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Cowen and Company, LLC (the “Underwriters”) and the Company’s President, Chief Executive Officer and Chairman of the Board of Directors, Richard L. Soloway (the “Selling Stockholder”), relating to the sale by the Selling Stockholder of an aggregate of 2,000,000 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”) owned by the Selling Stockholder in an underwritten secondary public offering, at a price to the public of $40.75 per share.”
Drilling Tools International Corp entered into Agreement and Plan of Merger with Superior Drilling Products, Inc. (effective 2024-03-06).
“On March 6, 2024, Drilling Tools International Corporation, a Delaware corporation (the “ Company ”), Superior Drilling Products, Inc., a Utah corporation (“ SDPI ”), DTI Merger Sub I, Inc., a Delaware corporation (“ Merger Sub I ”), and DTI Merger Sub II, LLC, a Delaware limited liability company (“ Merger Sub II ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”)”
Aetherium Acquisition Corp entered into Business Combination Agreement with Capital A Berhad, Capital A International, Aether Merger Sub Inc., Brand AA Sdn Bhd valued at $1,150,000,000 (effective 2024-02-28).
“On February 28, 2024, Aetherium Acquisition Corp, a Delaware corporation (“ Aetherium ” or “ Purchaser ”), entered into a definitive Business Combination Agreement”
MultiSensor AI Holdings, Inc. entered into Lock-Up Waiver Agreement (effective 2024-03-07).
“the Company entered into an agreement to waive the lock-up restrictions (the “Lock-Up Waiver Agreement”) with respect to 2,123,746 shares of the Company’s common stock”
MultiSensor AI Holdings, Inc. terminated Earnout Waiver Agreement (effective 2024-03-07).
“MultiSensor AI Holdings, Inc. (the “Company”) today entered into an agreement (the “Earnout Waiver Agreement”) to terminate a provision of the Business Combination Agreement”
Ventyx Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-03-06).
“In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated March 6, 2024 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares that are not then registered on an effective registration statement”
Ventyx Biosciences, Inc. entered into Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $100.0 million (effective 2024-03-06).
“On March 6, 2024, Ventyx Biosciences, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).”
FLYEXCLUSIVE INC. entered into Securities Purchase Agreement with EnTrust Emerald (Cayman) LP valued at approximately $25 million (effective 2024-03-04).
“On March 4, 2024 (the “Effective Date” or the “Initial Issue Date”), flyExclusive, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with EnTrust Emerald (Cayman) LP, a Cayman Islands limited partnership (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser 25,000 shares of Series A Non-Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), at a purchase price of $1,000 per share and a warrant (the “Warrant”) to purchase shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). The transaction closed on the Effective Date and provides the Company approximately $25 million of capital.”
EON Resources Inc. amended Amendment No. 1 to Common Stock Purchase Agreement with White Lion Capital, LLC valued at up to $150,000,000 in aggregate gross purchase price (effective 2024-03-07).
“On March 7, 2024, the Company entered into an Amendment No. 1 to Common Stock Purchase Agreement (the “Amendment”) with White Lion.”
Planet 13 Holdings Inc. entered into Warrant Agreement with Odyssey Transfer US Inc. valued at Warrant agreement governing terms of warrants sold in the offering (effective 2024-03-07).
“On March 7, 2024, the Company entered into a warrant agency agreement with the Company’s transfer agent, Odyssey Transfer US Inc. (“Odyssey”), which will also act as the warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Offering (the “Warrant Agreement”).”
Planet 13 Holdings Inc. entered into Underwriting Agreement with unknown valued at Underwriting Agreement for the offering of shares and warrants (effective 2024-03-07).
“A copy of the Underwriting Agreement is filed as Exhibit 1.1 hereto and is incorporated into this Item 1.01 by reference.”
Next Technology Holding Inc. entered into Purchase Agreement with certain existing shareholders of Future Dao Group Holding Limited valued at $13,396,000 (effective 2024-03-01).
“On March 1,2024, WeTrade Group Inc., a Wyoming corporation (“WeTrade”), entered into that certain share purchase agreement (the “Purchase Agreement”) with certain existing shareholders (the “Sellers”)of Future Dao Group Holding Limited, an exempted company incorporated and existing under the laws of the Cayman Islands(the “Target”),pursuant to which WeTrade agrees to purchase from the Sellers indirectly through Next Investment Group Limited,a wholly-owned subsidiary of WeTrade (“Next Investment”), and the Sellers agree to sell to Next Investment, an aggregate of 2,000 ordinary shares (the “Purchased Shares”) of the Target (the “Transaction”) at a per share purchase price of $6,698 per share for an aggregate purchase price of $13,396,000 (the “Purchase Price”).”
Momentus Inc. entered into Securities Purchase Agreement with an investor (the "Investor") valued at approximately $4.0 million (effective 2024-03-04).
“On March 4, 2024, Momentus Inc., a Delaware corporation (“Momentus” or the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”) for the purchase and sale to the Investor in a registered direct offering (the “Offering”) of (i) an aggregate of 1,320,000 shares of the Company’s Class A common stock, par value $0.00001 per share (the “Class A Stock”), at a purchase price of $0.865 per share of Class A Stock and one Warrant (as defined below), (ii) in lieu of Class A Stock, at the election of the Investor, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,304,280 shares of Class A Stock, at a purchase price of $0.86499 per Pre-Funded Warrant and one Warrant, and (iii) warrants to purchase 4,624,280 shares of Class A Stock (the “Warrants”).”
PennyMac Financial Services, Inc. entered into Series 2024-GT1 indenture supplement with qualified institutional buyers valued at $425 million (effective 2024-02-29).
“On February 29, 2024, PennyMac Financial Services, Inc. (the “Company”), through its indirect subsidiary, PNMAC GMSR ISSUER TRUST (the “Issuer Trust”), issued an aggregate principal amount of $425 million in secured term notes (the “2024-GT1 Notes”) to qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”).”
VNOM Sub, Inc. entered into Underwriting Agreement with Diamondback Energy, Inc. and J.P. Morgan Securities LLC, as representative of the several underwriters valued at $35.00 per share (effective 2024-03-05).
“On March 5, 2024, Viper Energy, Inc. (“Viper”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Diamondback Energy, Inc. (“Diamondback” or the “Selling Stockholder”) and J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriters”).”
Superior Drilling Products, Inc. entered into Agreement and Plan of Merger with Drilling Tools International Corporation, DTI Merger Sub I, Inc., DTI Merger Sub II, LLC (effective 2024-03-06).
“On March 6, 2024, Superior Drilling Products, Inc., a Utah corporation (the “ Company ” or “ we ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Drilling Tools International Corporation, a Delaware corporation (“ Parent ”), DTI Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“ Merger Sub I ”), and DTI Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Parent (“ Merger Sub II ” and together with Merger Sub I, “ Merger Subs ”).”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (effective 2022-03-03).
“On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).”
Lunai Bioworks Inc. terminated License Agreement with Weird Science LLC (effective 2024-03-01).
“On March 1, 2024, Renovaro Inc. (the “Company”) received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the “License Agreement”).”
Avinger Inc entered into Securities Purchase Agreement with Zylox-Tonbridge Medical Limited valued at up to an aggregate of $15 million (effective 2024-03-04).
“On March 4, 2024, in connection with the Strategic Collaboration, the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the “Purchaser”), entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company’s common stock,”
Avinger Inc entered into Strategic Cooperation and Framework Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
“on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the “Collaboration Agreement” and, together with the License Agreement, the “Strategic Collaboration”),”
Avinger Inc entered into License Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).
“On March 4, 2024, Avinger, Inc. (“Avinger” or the “Company”) entered into a License and Distribution Agreement (the “License Agreement”) with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) effective as of the Initial Closing (defined below),”
Orgenesis Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.3 million (effective 2024-03-03).
“On March 3, 2024, Orgenesis Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”), 2,272,719 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.03 per share (the “Shares”) and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $2.00 per share (collectively, the “Warrants”).”
Xtant Medical Holdings, Inc. amended Credit Agreements with MidCap Financial Trust and MidCap Funding IV Trust valued at $17,000,000 term facility and $17,000,000 revolving facility (effective 2024-03-07).
“On March 7, 2024 (the “Closing Date”), Xtant Medical Holdings, Inc. (the “Company”), as guarantor, and certain of its subsidiaries, Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc. and Surgalign SPV, Inc., as borrowers (collectively, the “Borrowers”), entered into (i) an Amended and Restated Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent, and the lenders from time to time party thereto, and (ii) an Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Funding IV Trust, in its capacity as agent, and the lenders from time to time party thereto.”
C-Bond Systems, Inc entered into Promissory Note and Securities Purchase Agreement with 1800 Diagonal Lending LLC valued at $157,000 aggregate principal amount; funded $125,000 on March 4, 2023 (effective 2024-03-01).
“On March 1, 2024, C-Bond Systems, Inc. (the “Company”) executed a Promissory Note (“Note”) in favor of 1800 Diagonal Lending LLC (the “Investor”) in the aggregate principal amount of $157,000 (the “Principal”), and an accompanying Securities Purchase Agreement (“SPA”).”
Keurig Dr Pepper Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $3.0 billion aggregate principal amount (effective 2024-03-07).
“On March 7, 2024, Keurig Dr Pepper Inc. (the “Company”) issued $3.0 billion aggregate principal amount of senior unsecured notes, consisting of $350.0 million aggregate principal amount of Floating Rate Senior Notes due 2027 (the “Floating Rate Notes”), $750.0 million aggregate principal amount of 5.100% Senior Notes due 2027 (the “2027 Notes”), $750.0 million aggregate principal amount of 5.050% Senior Notes due 2029 (the “2029 Notes”), $500.0 million aggregate principal amount of 5.200% Senior Notes due 2031 (the “2031 Notes”) and $650.0 million aggregate principal amount of 5.300% Senior Notes due 2034 (the “2034 Notes” and, together with the 2027 Notes, the 2029 Notes, and the 2031 Notes, the “Fixed Rate Notes,” and together with the Floating Rate Notes, the “Notes”), pursuant to an indenture, dated as of March 7, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Base Indenture”), as supplemented by the First Supplemental Indenture theret”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.